Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Immunotherapy Atezolizumab Receives FDA Approval for Advanced BRAF V600-Mutant MELANOMA

Immunotherapy Atezolizumab Receives FDA Approval for Advanced BRAF V600-Mutant MELANOMA

BRAF V600 mutation -positive, unresectable or metastatic cases of melanoma are treated with cobimetinib and vemurafenib in combination with atezolizumab (Tecentriq), an immunotherapy approved on 30 July 2020 by the US Food and Drug Administration (FDA). This is the first approved combination of BRAF inhibitors and immunotherapy.

The IMspire150 clinical trial

The efficacy of atezolizumab with cobimetinib and vemurafenib was evaluated in 514 patients in the double-blind, randomized (1:1), placebo-controlled, multicenter IMspire150 clinical trial. After a 28-day cycle of cobimetinib and vemurafenib, patients received oral tablets of 60 mg cobimetinib once daily and 720 mg vemurafenib twice daily, along with an infusion of 840 mg atezolizumab every 2 weeks or placebo. In the placebo arm, komimetinib was given as a single 60 mg dose daily (21 days on, 7 days off) and vemurafenib as 960 given 2 times daily.

The primary efficacy outcome measure was progression-free survival (PFS) in the trial.

Median PFS was 15.1 months in the atezolizumab arm and placebo patients had 10 months. Adding immunotherapy to treatment reduced the risk of cancer progression by 22%.

In patients with melanoma treated with atezolizumab in combination with cobimetinib and vemurafenib, the most common (20%) side effects were rash, musculoskeletal pain, nausea, fatigue, liver damage, pyrexia (fever), nausea, edema, stomatitis (mouth sores), hypothyroidism (thyroid dysfunction) and photosensitivity (excessive sensitivity to sunlight).

After completing a 28-day cycle of cobimetinib and vemurafenib, the recommended atezolizumab dose is 840 mg every 2 weeks. Oral cobimetinib 60 mg once daily (21 days on and 7 days off) and vemurafenib 720 mg twice daily are taken concurrently.

*

Sources

FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma.
fda.gov - 30 July 2020

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Immunotherapy Atezolizumab Receives FDA Approval for Advanced BRAF V600-Mutant MELANOMA

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy